200 related articles for article (PubMed ID: 36255733)
1. Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors.
Berman DM; Bell JI
Clin Cancer Res; 2023 Feb; 29(4):697-704. PubMed ID: 36255733
[TBL] [Abstract][Full Text] [Related]
2. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
[TBL] [Abstract][Full Text] [Related]
3. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
Chervin AS; Stone JD; Konieczna I; Calabrese KM; Wang N; Haribhai D; Dong F; White MK; Rodriguez LE; Bukofzer GT; Ellis PA; Cosgrove C; Hecquet C; Clarin JD; Palma JP; Reilly EB
Mol Cancer Ther; 2023 Aug; 22(8):903-912. PubMed ID: 37294945
[TBL] [Abstract][Full Text] [Related]
4. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
Baeuerle PA; Wesche H
Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
[TBL] [Abstract][Full Text] [Related]
5. T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy.
Li Y; Zhao W; Shen Y; Xu Y; Chen S; Pan L
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672132
[TBL] [Abstract][Full Text] [Related]
6. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.
Damato BE; Dukes J; Goodall H; Carvajal RD
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336704
[TBL] [Abstract][Full Text] [Related]
7. Tebentafusp: First Approval.
Dhillon S
Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
[TBL] [Abstract][Full Text] [Related]
8. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
[TBL] [Abstract][Full Text] [Related]
9. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.
Hung SI; Chu MT; Hou MM; Lee YS; Yang CK; Chu SY; Liu FY; Hsu HC; Pao SC; Teng YC; Chen CB; Chao A; Chung WH; Chang JW; Lai CH
Biomed Pharmacother; 2023 Dec; 169():115928. PubMed ID: 38011788
[TBL] [Abstract][Full Text] [Related]
10. The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy.
Arman I; Haus-Cohen M; Reiter Y
Cells; 2022 Dec; 12(1):. PubMed ID: 36611821
[TBL] [Abstract][Full Text] [Related]
11. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
12. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
13. A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen.
Bianchi V; Bulek A; Fuller A; Lloyd A; Attaf M; Rizkallah PJ; Dolton G; Sewell AK; Cole DK
J Biol Chem; 2016 Apr; 291(17):8951-9. PubMed ID: 26917722
[TBL] [Abstract][Full Text] [Related]
14. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
15. Generalizable design parameters for soluble T cell receptor-based T cell engagers.
Froning KJ; Sereno A; Huang F; Demarest SJ
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260435
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC; Border EC; Vieira JF; Pumphrey NJ
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
[TBL] [Abstract][Full Text] [Related]
18. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
19. T cell engagers in solid tumors kick the door down.
de Miguel M; Calvo E
Cancer Cell; 2021 Nov; 39(11):1461-1463. PubMed ID: 34752755
[TBL] [Abstract][Full Text] [Related]
20. A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.
Stone JD; Harris DT; Soto CM; Chervin AS; Aggen DH; Roy EJ; Kranz DM
Cancer Immunol Immunother; 2014 Nov; 63(11):1163-76. PubMed ID: 25082071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
